Department of Pharmaceutical Sciences, Lipscomb University College of Pharmacy , One University Park Drive, Nashville, Tennessee 37204, United States.
ACS Chem Neurosci. 2011 Apr 20;2(4):183-4. doi: 10.1021/cn200023v.
Qnexa (VI-0521) is an investigational fixed-dose combination drug of phentermine and topiramate currently in Phase III clinical trials for the treatment of obesity. Vivus, Inc. has demonstrated efficacy of their product and are currently addressing FDA safety concerns with the possibility of a New Drug Application (NDA) resubmission.
Qnexa(VI-0521)是一种正在进行 III 期临床试验的苯丁胺和托吡酯固定剂量组合药物,用于治疗肥胖症。Vivus,Inc. 已经证明了其产品的疗效,目前正在解决 FDA 的安全问题,有可能重新提交新药申请(NDA)。